DMD-Heart Protection Trial

• Research type

  Research Study

• Full title

  A double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males with DMD without echo-detectable left ventricular dysfunction

• IRAS ID

  1319

• Sponsor organisation

  Newcastle upon Tyne Hospitals NHS Foundation Trust

• Eudract number

  2007-005932-10

• ISRCTN Number

  ISRCTN50395346

• Research summary

  Boys with Duchene Muscular Dystrophy experience progressive muscle weakness as they grow up. This muscle weakness can also happen to their heart. Often this heart weakness does not show up until boys are teenagers. At this stage all that Doctors can do it is to try to treat an already weakened heart. The aim of the DMD Heart Protection study is to see whether it is possible to protect the heart muscle from getting weaker in boys with DMD by using two different medications in combination. One of the medications being used is an Angiotensin-converting enzyme inhibitor (ACE inhibitor), the other is a beta-blocker. ACE inhibitors are used to treat heart failure. Beta-blockers work by slowing down the rate heart beats and stop the heart beating so hard. DMD Heart Protection is a double blind (both participants and researchers are Ó?blind? to the medication taken) multi-centre (run in a number of different hospitals) study. For this study to be successful we need 140 boys with DMD and normally functioning hearts to take part.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  09/H0405/9

• Date of REC Opinion

  27 Feb 2009

• REC opinion

  Further Information Favourable Opinion